Study guide

Breast Pathology, Cancer Types, Staging & Adjuvant Therapies

BOC Certified Mastectomy Fitter CMF

Track your progress as you read

Finished sections get a check mark.

1 Facilities Management, Safety & Regulatory Compliance

DMEPOS Supplier Standards, Quality Standards & BOC Facility Accreditation Fitting Room Design, Measuring Instruments & Inventory Controls Environmental Safety, OSHA Regulations & Infection Control Facility Policies, Record Retention & HIPAA Privacy/Security Compliance

2 Professional Practice, Scope of Practice & Ethics

Upholding Patient Confidentiality & Dignity in Clinical Encounters BOC Certification Eligibility, CEU Requirements & Recertification Policy Performance Improvement Systems & Inter-Professional Education BOC CMF Scope of Practice & BOC Code of Ethics Compliance

3 Breast Anatomy, Oncology, Surgical Procedures & Reconstruction

Breast, Chest Wall, Musculoskeletal & Lymphatic System Anatomy Breast Pathology, Cancer Types, Staging & Adjuvant Therapies Breast Conserving Surgery & Mastectomy Classifications Breast Reconstruction Modalities, Tissue Expanders & Going Flat

4 Patient Intake, Physical Assessment & Prescription Verification

Patient Relationship, Clinical Interview & Financial Counseling Evaluating Skin Condition, Healing Readiness, ROM, Strength & Dexterity Assessing Post-Surgical Edema, Lymphedema Risk & Precautions Prescription Assessment, Standard Written Orders & Physician Verification

5 Patient Communication, Psychosocial Care & Care Coordination

Explaining Device Objectives, Procedures & Product Options Psychosocial Impact, Grief, Body Image & Family Dynamics Trauma-Informed Fitting, Special Populations & Patient Autonomy Inter-Professional Communication, Clinical Progress Notes & Referrals

6 Anthropometric Landmarks, Measurement & Post-Surgical Garments

Anatomical Landmarks & Patient Positioning for Measurement Unilateral, Bilateral & Post-Reconstruction Measurement Techniques Post-Surgical Camisoles, Drain Management & Transitional Forms Lymphedema Sleeves & Gradient Compression Garment Selection

7 External Breast Prostheses & Post-Mastectomy Bra Selection

Silicone Weighted vs. Lightweight, Foam & Leisure Prostheses Prosthesis Shapes, Profiles, Partial Shapers & Attachable Designs Custom-Fabricated Breast Prostheses (3D Scanning) & Nipple Prostheses Post-Mastectomy Bra Engineering, Pocket Construction & Specialty Garments

8 Product Alignment, Delivery, Medicare Billing & Follow-Up

Fitting Alignment, Biomechanical Balance & Bra/Form Troubleshooting Donning/Doffing Instruction, Return Demonstration & Product Care Proof of Delivery, HCPCS L-Codes, Modifiers, ABNs & WHCRA Coverage Follow-Up Evaluation, Chart Updates & Replacement Schedules

Breast Pathology, Cancer Types, Staging & Adjuvant Therapies

Key Takeaways Explain This Topic AI

Ductal Carcinoma In Situ (DCIS, Stage 0) is confined within the ductal basement membrane without metastatic potential, whereas Invasive Ductal Carcinoma (IDC, 75%-80% of cases) and Invasive Lobular Carcinoma (ILC, 10%-15%, growing in single-file chains) breach the basement membrane.

Inflammatory Breast Cancer (IBC) is an aggressive T4d (Stage IIIB-IV) malignancy where tumor emboli obstruct dermal lymphatics, causing rapid diffuse erythema and peau d'orange; it requires neoadjuvant chemotherapy, modified radical mastectomy, and post-mastectomy radiation.

Poland syndrome involves congenital unilateral absence or hypoplasia of the sternocostal head of the pectoralis major muscle and ipsilateral breast/nipple, representing a classic indication for a custom-fabricated (L8035) or asymmetrical breast prosthesis.

Radiation dermatitis with moist desquamation contraindicates weighted or adhesive silicone forms; chemotherapy-induced peripheral neuropathy (CIPN) indicates front-closure bras; implanted Port-a-Caths require strap/prosthesis clearance; and aromatase inhibitors cause hot flashes and arthralgias requiring breathable temperature-regulating products.

Last updated: October 2026

Benign Breast Conditions, Congenital Anomalies & Non-Invasive ( In Situ ) Neoplasms

During the intake interview and review of medical records, a Certified Mastectomy Fitter encounters both benign and malignant breast pathologies, as well as congenital chest wall anomalies that require prosthetic intervention.

Benign Breast Conditions & Congenital Anomalies

Fibrocystic Breast Changes: The most common benign condition of the breast, characterized by hormone-sensitive fluid-filled cysts, stromal fibrosis, and epithelial hyperplasia. Patients experience cyclic bilateral breast swelling, nodularity, and premenstrual tenderness ( mastalgia ). For the fitter, pronounced cyclic swelling in a conserved or contralateral breast may require a supportive, non-underwire bra with flexible cup materials.

Fibroadenoma: A benign, well-circumscribed, mobile, rubbery fibroepithelial tumor composed of stromal and epithelial elements, occurring most frequently in women under age 35. Large or multiple excised fibroadenomas (such as giant juvenile fibroadenomas or benign phyllodes tumors) can leave localized volume deficits requiring a partial breast shaper.

Intraductal Papilloma: A small, benign wart-like papillary growth within a major lactiferous duct near the subareolar sinus; it is the most common cause of spontaneous, unilateral serous or bloody nipple discharge.

Mastitis and Subareolar Abscess: Parenchymal inflammation or bacterial infection (most commonly Staphylococcus aureus during lactation) presenting with localized erythema, warmth, edema, tenderness, and systemic fever/leukocytosis. Because Inflammatory Breast Cancer (IBC) closely mimics acute mastitis, any non-lactational erythema and edema that fails to resolve promptly with antibiotics requires biopsy.

Poland Syndrome: A rare congenital anomaly characterized by unilateral absence or hypoplasia of the sternocostal head of the pectoralis major muscle , accompanied by hypoplasia or absence of the ipsilateral breast and nipple-areola complex ( hypomastia, amastia, or athelia ), scarcity of subcutaneous fat, potential absence of costal cartilages (ribs 2-5), and occasional ipsilateral hand anomalies ( syndactyly or brachydactyly ). Poland syndrome is a classic non-oncological medical indication for a custom-fabricated breast prosthesis ( L8035 ) or an asymmetrical partial/full prosthesis designed to fill both the anterior pectoral deficiency and the missing breast mound.

Non-Invasive ( In Situ ) Breast Neoplasms

The defining histopathological boundary separating in situ (non-invasive) disease from invasive carcinoma is the epithelial basement membrane of the mammary ducts and lobules:

Ductal Carcinoma In Situ (DCIS — AJCC Stage 0): Malignant proliferation of ductal epithelial cells that remains completely confined within the basement membrane of the mammary duct lumen without stromal invasion. Because the cells have not crossed the basement membrane to reach lymphatic or vascular channels, pure DCIS cannot metastasize. However, untreated DCIS can progress to invasive ductal carcinoma, so it is treated surgically via lumpectomy (usually followed by whole-breast radiation) or simple mastectomy (especially when diffuse, multicentric microcalcifications span multiple quadrants).

Lobular Carcinoma In Situ (LCIS): A non-invasive proliferation of discohesive cells filling and distending the terminal duct lobular units (TDLUs) while respecting the basement membrane. Unlike DCIS, classic LCIS is treated in modern oncology and the AJCC staging system as a high-risk biological marker for developing invasive cancer in either breast (conferring a 7- to 10-fold increased risk distributed equally between the ipsilateral and contralateral breasts) rather than a localized premalignant lesion. Management includes intensive bilateral imaging surveillance, risk-reducing endocrine therapy, or bilateral prophylactic (risk-reducing) simple mastectomy .

Invasive Breast Carcinomas, TNM Staging & Molecular Biomarkers

When malignant cells breach the basement membrane and infiltrate the surrounding mammary stroma, the tumor is classified as an invasive (infiltrating) carcinoma capable of regional lymphatic and distant hematogenous spread:

Invasive Ductal Carcinoma (IDC — Invasive Breast Carcinoma of No Special Type [NST]): The most prevalent breast malignancy, accounting for 75% to 80% of all invasive breast cancers. IDC typically incites a dense fibrotic ( desmoplastic ) stromal response that produces a firm, irregular, palpable lump and a spiculated mass with pleomorphic microcalcifications on diagnostic mammography.

Invasive Lobular Carcinoma (ILC): Accounts for 10% to 15% of invasive breast cancers. Histologically, ILC cells lack the cell-to-cell adhesion protein E-cadherin , causing malignant cells to infiltrate the stroma in single-file linear strands ("Indian file" pattern) encircling existing ducts without provoking a discrete desmoplastic mass. Consequently, ILC is harder to detect on physical exam or standard mammography—often presenting as subtle architectural distortion or diffuse thickening—and has a higher incidence of multifocal, multicentric, and bilateral presentation .

Inflammatory Breast Cancer (IBC): A rare ( 1% to 5% ) but highly aggressive clinicopathological form of invasive breast cancer classified at presentation as T4d (at least Stage IIIB) . Tumor emboli invade and plug the superficial dermal lymphatic vessels , causing rapid onset (within weeks to less than 6 months) of diffuse erythema and warmth involving at least one-third of the breast skin, marked breast edema, and widespread peau d'orange , often without a discrete underlying palpable mass. Because the entire dermal lymphatic network is involved, breast-conserving surgery and immediate breast reconstruction are contraindicated ; standard care requires neoadjuvant systemic chemotherapy, Modified Radical Mastectomy (MRM) , and post-mastectomy chest wall and regional nodal radiation.

Paget's Disease of the Breast (Nipple): A rare manifestation (1% to 4% of cases) in which malignant glandular epithelial cells ( Paget cells ) extend from an underlying retroareolar DCIS or invasive ductal carcinoma up the lactiferous ducts into the epidermis of the nipple and areola. It presents clinically as chronic, unilateral eczematous crusting, scaling, erythema, pruritus, or ulceration of the nipple skin that frequently destroys the nipple projection.

AJCC TNM Staging System & Molecular Subtypes

The American Joint Committee on Cancer (AJCC) stages breast cancer anatomically using the TNM classification combined with prognostic biomarkers (grades and receptor status) into Stages 0 through IV :

TNM Component Classification Categories & Clinical Definitions

T (Primary Tumor) TX: Primary tumor cannot be assessed; T0: No evidence of primary tumor; Tis: Carcinoma in situ (DCIS or Paget's disease of the nipple with no invasive carcinoma); T1: Invasive tumor <= 2 cm in greatest dimension; T2: Tumor > 2 cm but <= 5 cm ; T3: Tumor > 5 cm ; T4: Tumor of any size with direct extension to the chest wall/ribs/intercostal/serratus muscles ( T4a , note: invasion of pectoral muscle alone does not qualify as T4a), skin ulceration/ipsilateral satellite skin nodules/ peau d'orange ( T4b ), both T4a and T4b ( T4c ), or Inflammatory Breast Carcinoma ( T4d ).

N (Regional Lymph Nodes) N0: No regional lymph node metastases; N1: Metastasis to movable ipsilateral Level I-II axillary lymph node(s); N2: Metastasis to ipsilateral Level I-II axillary nodes fixed or matted to one another, or clinically apparent internal mammary nodes without axillary metastasis; N3: Metastasis to ipsilateral infraclavicular ( Level III ) axillary nodes ( N3a ), internal mammary plus Level I-II axillary nodes ( N3b ), or ipsilateral supraclavicular lymph nodes ( N3c ).

M (Distant Metastasis) M0: No clinical or radiographic evidence of distant metastasis; M1: Distant detectable metastasis (most commonly to bone, lungs, liver, or brain ), which defines Stage IV metastatic breast cancer.

Every invasive breast tumor is also assayed for three predictive molecular biomarkers and hereditary susceptibility genes:

Estrogen Receptor (ER+) and Progesterone Receptor (PR+): Present in ~70%-75% of breast cancers ( Luminal A/B subtypes); tumor growth is driven by estrogen/progesterone, making the patient a candidate for 5 to 10 years of adjuvant endocrine (hormone) therapy .

HER2/neu (Human Epidermal Growth Factor Receptor 2): Overexpressed or gene-amplified in ~15%-20% of breast cancers; confers rapid proliferation but responds to targeted anti-HER2 therapies such as trastuzumab (Herceptin) and pertuzumab.

Triple-Negative Breast Cancer (TNBC — ER-negative, PR-negative, HER2-negative): Accounts for ~10%-15% of cases; lacks all three receptors, tends to be high histological grade with earlier visceral recurrence risk, is treated with systemic chemotherapy and immunotherapy rather than hormone or HER2 agents, and occurs frequently in BRCA1 mutation carriers.

BRCA1 and BRCA2 Germline Mutations: High-penetrance autosomal dominant tumor-suppressor gene mutations that impair homologous recombination DNA repair, conferring a high lifetime breast cancer risk (roughly 55%–72% for BRCA1 and 45%–69% for BRCA2 carriers) (and elevated ovarian, pancreatic, prostate, and male breast cancer risk, particularly with BRCA2 ). Patients testing positive for pathogenic BRCA1/2 variants frequently undergo bilateral risk-reducing (prophylactic) mastectomy .

Note

Clinical Distinction: Inflammatory Breast Cancer (T4d) vs. Acute Infectious Mastitis: Both Inflammatory Breast Cancer (IBC) and acute mastitis present with a warm, swollen, erythematous breast and skin thickening. However, IBC is a Stage IIIB-IV malignancy ( T4d ) caused by tumor emboli obstructing dermal lymphatics rather than bacterial infection. Because IBC requires aggressive trimodality therapy—neoadjuvant chemotherapy, Modified Radical Mastectomy, and extensive post-mastectomy radiation to the chest wall and regional lymph nodes—patients surviving IBC present to the CMF with thin, heavily irradiated, fibrotic chest wall skin and a high risk of secondary lymphedema after axillary dissection plus regional nodal radiation.

Adjuvant & Neoadjuvant Oncology Therapies and Direct Mastectomy Fitting Implications

Oncological treatment rarely ends in the operating room. Neoadjuvant therapy (administered before surgery to shrink locally advanced tumors and downstage the axilla) and adjuvant therapy (administered after surgery to eradicate micrometastatic disease) cause specific physiological side effects that directly dictate garment timing, material selection, and prosthesis weight.

1. Radiation Therapy (External Beam Radiation Therapy [EBRT] & Brachytherapy)

Radiation is delivered after lumpectomy (whole-breast or accelerated partial-breast irradiation) or after mastectomy (Post-Mastectomy Radiation Therapy [PMRT] to the chest wall and regional nodes) over 3 to 6 weeks:

Acute Radiation Sequelae (During treatment through 4 to 8 weeks post-treatment): Ionizing radiation damages rapidly dividing basal keratinocytes, producing acute radiation dermatitis —progressing from brisk erythema, warmth, edema, pruritus, and burning chest wall hyperesthesia to dry desquamation (flaking, peeling epidermis) and moist desquamation (epidermal sloughing with raw dermis and serous exudate). While skin is actively irradiated or exhibiting moist desquamation, weighted silicone prostheses ( L8030 ), self-supporting adhesive prostheses ( L8031 ), and tight or underwire bras are strictly contraindicated because friction, heat retention, and weight shear fragile epidermis. During this phase, the CMF fits a loose, seamless cotton post-surgical camisole ( L8015 ) or ultra-soft pocketed leisure bra with an unweighted fiberfill puff.

Chronic / Late Radiation Sequelae (Months to years post-treatment): Radiation induces obliterative endarteritis and fibroblast activation, causing chronic subcutaneous radiation fibrosis , dermal thickening, loss of tissue compliance, permanent telangiectasias (spidery dilated superficial capillaries), hyper- or hypopigmentation, and rib fragility. In patients who underwent lumpectomy plus radiation, progressive fibrosis causes retraction and volume shrinkage of the irradiated breast , elevating the inframammary fold and creating increasing asymmetry compared to the natural contralateral breast—an indication for a partial silicone breast shaper/equalizer . Radiation to the axilla or supraclavicular fossa also compounds lymphedema risk .

2. Systemic Chemotherapy

Cytotoxic regimens (such as taxanes [paclitaxel, docetaxel], anthracyclines [doxorubicin], cyclophosphamide, and platinum salts) produce four major fitting challenges:

Chemotherapy-Induced Peripheral Neuropathy (CIPN): Taxanes and platinum agents cause dose-dependent sensory axonal neuropathy in a "stocking-and-glove" distribution, producing numbness, paresthesia, burning pain, and loss of fine pinch dexterity in the fingertips. Patients with CIPN struggle to manipulate tiny posterior hook-and-eye closures behind their back and benefit from front-closure mastectomy bras (large hooks, Velcro, or front zippers) or step-in styles.

Implanted Venous Access Port (Port-a-Cath): A subcutaneous titanium/plastic reservoir connected to a central venous catheter is commonly implanted on the superior anterior chest wall just inferior to the clavicle (usually on the contralateral side). The CMF must visually and manually locate the raised port bulge during assessment and ensure that neither the bra strap nor the superior border of the breast prosthesis rests over, compresses, or chafes the port site . Wide cushioned straps or adjusted strap trajectories are used to bridge or bypass the port.

Weight Fluctuations & Fluid Retention: Corticosteroid pre-medications, chemotherapy-induced ovarian suppression, and gastrointestinal side effects frequently trigger weight gains or losses of 10 to 25+ pounds . Because the contralateral natural breast is predominantly adipose tissue, significant weight change alters both under-bust band size and natural breast cup volume. Re-measure whenever weight changes noticeably. Medicare's External Breast Prostheses policy does not set a weight threshold. It replaces a prosthesis of the same type early only when the item is lost or irreparably damaged. It covers a different type of prosthesis at any time when the patient's medical condition changes and the treating practitioner writes a new order explaining the need.

Fatigue, Alopecia & Immunosuppression (Neutropenia): Require energy-conserving fitting appointments and scrupulous infection-control disinfection of all fitting room surfaces and try-on garments.

3. Endocrine (Hormone) Therapy

Patients with ER+/PR+ breast cancer take oral Tamoxifen (a Selective Estrogen Receptor Modulator [SERM]) or Aromatase Inhibitors (AIs — Anastrozole, Letrozole, Exemestane) for 5 to 10 years:

Therapy Category Common Agents Primary Side Effects Direct CMF Fitting Modifications

Radiation Therapy EBRT, PMRT, Brachytherapy Acute radiation dermatitis (erythema, dry/moist desquamation); chronic fibrosis, telangiectasia, breast retraction Defer definitive weighted ( L8030 ) or adhesive ( L8031 ) silicone until the skin has fully healed and the physician clears fitting; use soft cotton camisole/fiberfill during acute phase; fit soft-gel-backed or partial forms for chronic fibrosis/retraction

Chemotherapy Paclitaxel, Docetaxel, Doxorubicin, Carboplatin CIPN (fingertip numbness/loss of pinch), infraclavicular Port-a-Cath, 10-25 lb weight shifts, fatigue Recommend front-closure bras for CIPN; route straps and upper cup/form edges clear of the Port-a-Cath ; re-measure band and cup whenever weight changes noticeably

Endocrine Therapy (AIs & SERMs) Anastrozole, Letrozole, Exemestane, Tamoxifen AI-induced arthralgia (hand/wrist/shoulder joint stiffness), vasomotor hot flashes/sweats , osteoporosis/bone loss Select breathable microfiber pockets , channeled/air-flow or phase-change material (PCM) temperature-regulating forms for hot flashes, lightweight silicone forms for osteoporotic spine protection, and front closures for hand arthralgia

Warning

Port-a-Cath Protection & Active Radiation Skin Contraindications: Two clinical safety rules must never be violated during a mastectomy fitting: (1) Never fit a weighted silicone or attachable adhesive prosthesis over skin with active radiation dermatitis or moist desquamation —wait until the epidermis is fully re-epithelialized and cleared for definitive fitting; and (2) Never allow a narrow bra strap, underwire, or the top rim of a prosthesis to press directly on a subcutaneous Port-a-Cath , which can cause skin erosion over the port septum, localized pain, or catheter pinch-off.

Clinical Scenario: Adapting the Fitting Plan for Taxane Neuropathy and Aromatase Inhibitor Side Effects

Patient Presentation: A 63-year-old woman presents 10 weeks after a left simple mastectomy. She recently completed adjuvant docetaxel chemotherapy via a right infraclavicular Port-a-Cath (which remains implanted) and started oral letrozole (an aromatase inhibitor) three weeks ago. She reports persistent numbness and tingling in both hands, morning stiffness in her fingers and shoulders, and frequent drenching hot flashes.

CMF Fitting Solution:

Closure Adaptation: Because taxane-induced peripheral neuropathy (CIPN) and letrozole-induced hand arthralgia impair fine pinch dexterity and posterior reach, the CMF selects a front-closure pocketed mastectomy bra with large, easy-grip fasteners.

Port-a-Cath Clearance: The CMF verifies that the right shoulder strap is wide, padded, and positioned laterally enough (or cushioned with a silicone/foam strap pad) so that it does not rub or compress the raised right infraclavicular port reservoir.

Thermal Regulation: To counteract letrozole-induced vasomotor hot flashes and chest wall perspiration, the CMF fits a lightweight silicone prosthesis featuring a ribbed/channeled back and integrated phase-change material (PCM) inside a moisture-wicking microfiber pocket.